However, it has been reported that diffuse GC as well as lobular breast carcinomas exhibited a reduced HER2 rate in comparison to frequent mutations of E-cadherin, with an inverse association [11, 22–24]; by contrast, in more than 50% of invasive cribriform breast carcinomas, a linear direct association between HER2 positivity and E-cadherin immunoreactivity has been already documented [25]. The gene discussed is ERBB2; the disease is cribriform carcinoma of breast.